Risk factors and outcome of hyponatremia in patients with Guillain-Barré syndrome.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
19 Jul 2024
Historique:
received: 14 01 2024
accepted: 11 07 2024
medline: 20 7 2024
pubmed: 20 7 2024
entrez: 19 7 2024
Statut: epublish

Résumé

The objective of the present study was to evaluate the risk factors and outcomes associated with hyponatremia in patients with Guillain-Barré syndrome (GBS). We retrospectively studied 80 consecutive patients with GBS who visited our hospital and compared clinical, laboratory, and electrophysiological findings of patients with and without hyponatremia. Disability was evaluated using the Hughes grading system. Of the 80 patients, 18 (23%) had hyponatremia. Hyponatremia was significantly associated with older age (P = 0.003), urinary retention (P < 0.0001), Hughes grade ≥ 4 at admission and nadir (P = 0.003 and P < 0.001, respectively), acute inflammatory demyelinating polyneuropathy subtype (P = 0.017), sepsis (P = 0.001), mechanical ventilator support (P = 0.013), longer hospitalization length of stay (P < 0.0001), and inability to walk independently at 6 months (P < 0.001). Multivariate analysis performed to assess the risk factors of hyponatremia revealed that urinary retention (odds ratio [OR] 30.7, 95% confidence interval [CI] 3.6-264.4; P = 0.002) and mechanical ventilator support (OR 13.8, 95% CI 1.6-118.0; P = 0.017) were significant independent risk factors of hyponatremia. In assessing the outcomes of patients with hyponatremia, multivariate analysis showed that hyponatremia was independently associated with hospitalization length of stay ≥ 60 days and inability to walk independently at 6 month, with the former showing statistical significance but the latter not (OR 9.3, 95% CI 1.8-47.7; P = 0.007 and OR 4.9, 95% CI 0.9-26.3; P = 0.066, respectively). Therefore, we demonstrate that, along with mechanical ventilator support, urinary retention-possibly indicating autonomic dysfunction-is a risk factor of hyponatremia in GBS. Moreover, we confirm that hyponatremia is associated with poor outcome in GBS.

Identifiants

pubmed: 39030260
doi: 10.1038/s41598-024-67427-6
pii: 10.1038/s41598-024-67427-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

16664

Informations de copyright

© 2024. The Author(s).

Références

van Doorn, P. A., Ruts, L. & Jacobs, B. C. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol. 7, 939–950. https://doi.org/10.1016/S1474-4422(08)70215-1 (2008).
doi: 10.1016/S1474-4422(08)70215-1 pubmed: 18848313
Kaida, K. Guillain-Barre syndrome. Adv. Exp. Med. Biol. 1190, 323–331. https://doi.org/10.1007/978-981-32-9636-7_20 (2019).
doi: 10.1007/978-981-32-9636-7_20 pubmed: 31760653
Yuki, N. & Hartung, H. P. Guillain-Barre syndrome. N. Engl. J. Med. 366, 2294–2304. https://doi.org/10.1056/NEJMra1114525 (2012).
doi: 10.1056/NEJMra1114525 pubmed: 22694000
Kuwabara, S. & Yuki, N. Axonal Guillain-Barre syndrome: Concepts and controversies. Lancet Neurol. 12, 1180–1188. https://doi.org/10.1016/S1474-4422(13)70215-1 (2013).
doi: 10.1016/S1474-4422(13)70215-1 pubmed: 24229616
Kusunoki, S., Willison, H. J. & Jacobs, B. C. Antiglycolipid antibodies in Guillain-Barre and Fisher syndromes: Discovery, current status and future perspective. J. Neurol. Neurosurg. Psychiatry 92, 311–318. https://doi.org/10.1136/jnnp-2020-325053 (2021).
doi: 10.1136/jnnp-2020-325053 pubmed: 33376111
Saifudheen, K., Jose, J., Gafoor, V. A. & Musthafa, M. Guillain-Barre syndrome and SIADH. Neurology 76, 701–704. https://doi.org/10.1212/WNL.0b013e31820d8b40 (2011).
doi: 10.1212/WNL.0b013e31820d8b40 pubmed: 21339497
Hiew, F. L., Winer, J. B. & Rajabally, Y. A. Hyponatraemia in Guillain-Barre syndrome revisited. Acta Neurol. Scand. 133, 295–301. https://doi.org/10.1111/ane.12459 (2016).
doi: 10.1111/ane.12459 pubmed: 26184092
Rumalla, K., Reddy, A. Y., Letchuman, V. & Mittal, M. K. Hyponatremia in Guillain-Barre syndrome. J. Clin. Neuromuscul. Dis. 18, 207–217. https://doi.org/10.1097/CND.0000000000000157 (2017).
doi: 10.1097/CND.0000000000000157 pubmed: 28538251
Wang, Y. & Liu, J. Hyponatremia is a predictor for poor outcome in Guillain-Barre syndrome. Neurol. Res. 37, 347–351. https://doi.org/10.1179/1743132814Y.0000000455 (2015).
doi: 10.1179/1743132814Y.0000000455 pubmed: 25366666
Chakraborty, T., Kramer, C. L., Wijdicks, E. F. M. & Rabinstein, A. A. Dysautonomia in Guillain-Barre syndrome: Prevalence, clinical spectrum, and outcomes. Neurocrit. Care 32, 113–120. https://doi.org/10.1007/s12028-019-00781-w (2020).
doi: 10.1007/s12028-019-00781-w pubmed: 31297663
Sipila, J. O., Kauko, T. & Soilu-Hanninen, M. Admission sodium level and prognosis in adult Guillain-Barre syndrome. Int. J. Neurosci. 127, 344–349. https://doi.org/10.3109/00207454.2016.1163551 (2017).
doi: 10.3109/00207454.2016.1163551 pubmed: 26971365
Gagliardi, D. et al. Sodium levels predict disability at discharge in Guillain-Barre syndrome: A retrospective cohort study. Front. Neurol. 12, 729252. https://doi.org/10.3389/fneur.2021.729252 (2021).
doi: 10.3389/fneur.2021.729252 pubmed: 34557155 pmcid: 8453067
Asbury, A. K. & Cornblath, D. R. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann. Neurol. 27(Suppl), S21-24. https://doi.org/10.1002/ana.410270707 (1990).
doi: 10.1002/ana.410270707 pubmed: 2194422
Yuki, N. et al. Guillain-Barre syndrome associated with normal or exaggerated tendon reflexes. J. Neurol. 259, 1181–1190. https://doi.org/10.1007/s00415-011-6330-4 (2012).
doi: 10.1007/s00415-011-6330-4 pubmed: 22143612
Uncini, A., Notturno, F. & Kuwabara, S. Hyper-reflexia in Guillain-Barre syndrome: Systematic review. J. Neurol. Neurosurg. Psychiatry 91, 278–284. https://doi.org/10.1136/jnnp-2019-321890 (2020).
doi: 10.1136/jnnp-2019-321890 pubmed: 31937584
Hughes, R. A., Newsom-Davis, J. M., Perkin, G. D. & Pierce, J. M. Controlled trial prednisolone in acute polyneuropathy. Lancet 2, 750–753. https://doi.org/10.1016/s0140-6736(78)92644-2 (1978).
doi: 10.1016/s0140-6736(78)92644-2 pubmed: 80682
Kimura, J. Electrodiagnosis in Deseases of Nerve and Muscle: Principles and Practice 2nd edn. (F.A. Davis, 1989).
Rajabally, Y. A., Durand, M. C., Mitchell, J., Orlikowski, D. & Nicolas, G. Electrophysiological diagnosis of Guillain-Barre syndrome subtype: Could a single study suffice?. J. Neurol. Neurosurg. Psychiatry 86, 115–119. https://doi.org/10.1136/jnnp-2014-307815 (2015).
doi: 10.1136/jnnp-2014-307815 pubmed: 24816419
Rajabally, Y. A. & Uncini, A. Outcome and its predictors in Guillain-Barre syndrome. J. Neurol. Neurosurg. Psychiatry 83, 711–718. https://doi.org/10.1136/jnnp-2011-301882 (2012).
doi: 10.1136/jnnp-2011-301882 pubmed: 22566597
Walgaard, C. et al. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology 76, 968–975. https://doi.org/10.1212/WNL.0b013e3182104407 (2011).
doi: 10.1212/WNL.0b013e3182104407 pubmed: 21403108 pmcid: 3059137
Khedr, E. M., Mahmoud, D. M., Ahmed, G. K. & Haridy, N. A. Predictors of long-term health-related quality of life in Guillain-Barre syndrome: A hospital-based study. Clin. Neurol. Neurosurg. 235, 108026. https://doi.org/10.1016/j.clineuro.2023.108026 (2023).
doi: 10.1016/j.clineuro.2023.108026 pubmed: 37913589
Hughes, R. A. et al. Supportive care for patients with Guillain-Barre syndrome. Arch. Neurol. 62, 1194–1198. https://doi.org/10.1001/archneur.62.8.1194 (2005).
doi: 10.1001/archneur.62.8.1194 pubmed: 16087757
Netto, A. B. et al. Complications in mechanically ventilated patients of Guillain-Barre syndrome and their prognostic value. J. Neurosci. Rural Pract. 8, 68–73. https://doi.org/10.4103/0976-3147.193542 (2017).
doi: 10.4103/0976-3147.193542 pubmed: 28149085 pmcid: 5225726
Lenhard, T., Grimm, C. & Ringleb, P. A. Renal salt wasting as part of dysautonomia in Guillain-Barre syndrome. J. Neurol. Neurosurg. Psychiatry 82, 1051–1053. https://doi.org/10.1136/jnnp.2009.192369 (2011).
doi: 10.1136/jnnp.2009.192369 pubmed: 20732865
Kumar, M., Kalita, J. & Misra, U. K. Renal salt wasting in Guillain-Barre syndrome. Postgrad. Med. J. 95, 628–629. https://doi.org/10.1136/postgradmedj-2019-136870 (2019).
doi: 10.1136/postgradmedj-2019-136870 pubmed: 31375556
Zaeem, Z., Siddiqi, Z. A. & Zochodne, D. W. Autonomic involvement in Guillain-Barre syndrome: An update. Clin. Auton. Res. 29, 289–299. https://doi.org/10.1007/s10286-018-0542-y (2019).
doi: 10.1007/s10286-018-0542-y pubmed: 30019292
Lichtenfeld, P. Autonomic dysfunction in the Guillain-Barre syndrome. Am. J. Med. 50, 772–780. https://doi.org/10.1016/0002-9343(71)90185-9 (1971).
doi: 10.1016/0002-9343(71)90185-9 pubmed: 5089852
Singh, N. K., Jaiswal, A. K., Misra, S. & Srivastava, P. K. Assessment of autonomic dysfunction in Guillain-Barre syndrome and its prognostic implications. Acta Neurol. Scand. 75, 101–105. https://doi.org/10.1111/j.1600-0404.1987.tb07902.x (1987).
doi: 10.1111/j.1600-0404.1987.tb07902.x pubmed: 3577674
Zochodne, D. W. Autonomic involvement in Guillain-Barre syndrome: A review. Muscle Nerve 17, 1145–1155. https://doi.org/10.1002/mus.880171004 (1994).
doi: 10.1002/mus.880171004 pubmed: 7935521
Colls, B. M. Guillain-Barre syndrome and hyponatraemia. Intern. Med. J. 33, 5–9. https://doi.org/10.1046/j.1445-5994.2002.00322.x (2003).
doi: 10.1046/j.1445-5994.2002.00322.x pubmed: 12534871
Cui, H. et al. Inappropriate antidiuretic hormone secretion and cerebral salt-wasting syndromes in neurological patients. Front. Neurosci. 13, 1170. https://doi.org/10.3389/fnins.2019.01170 (2019).
doi: 10.3389/fnins.2019.01170 pubmed: 31780881 pmcid: 6857451
Posner, J. B., Ertel, N. H., Kossmann, R. J. & Scheinberg, L. C. Hyponatremia in acute polyneuropathy. Four cases with the syndrome of inappropriate secretion of antidiuretic hormone. Arch. Neurol. 17, 530–541. https://doi.org/10.1001/archneur.1967.00470290084011 (1967).
doi: 10.1001/archneur.1967.00470290084011 pubmed: 4293349
Hemmer, M., Viquerat, C. E., Suter, P. M. & Vallotton, M. B. Urinary antidiuretic hormone excretion during mechanical ventilation and weaning in man. Anesthesiology 52, 395–400. https://doi.org/10.1097/00000542-198005000-00004 (1980).
doi: 10.1097/00000542-198005000-00004 pubmed: 7377572

Auteurs

Shoji Ogawa (S)

Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.

Takafumi Hosokawa (T)

Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan. takafumi.hosokawa@ompu.ac.jp.

Chizuko Hayakawa (C)

Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.

Taiki Sawai (T)

Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.

Kensuke Kakiuchi (K)

Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.

Daisuke Nishioka (D)

Department of Medical Statistics, Research and Development Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.

Yukiyo Yoshimoto (Y)

Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.

Yuichi Masuda (Y)

Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.

Yoshitsugu Nakamura (Y)

Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.

Shin Ota (S)

Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.

Shigeki Arawaka (S)

Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH